Prospective Non-Interventional Real-Life Study of Effectiveness, Safety, Adherence, and Health-Related Quality of Life in Adult Patients receiving Elvitegravir/Cobicistat/Emtricitabine/Tenofovir alafenamide (E/C/F/TAF) or Rilpivirine/Emtricitabine/Tenofovir alafenamide (R/F/TAF) for HIV-1 Infection in France (TARANIS)

15/11/2016
22/02/2024
EU PAS number:
EUPAS16212
Study
Finalised
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

protocol GS-FR-292-4043 original 26092016 final

English (1.23 MB - PDF) View document
Updated protocol

GS-FR-292-4043-appendix-16.1.1-protocol amendment 2_f-redact

First published: 22/02/2024
English (3.58 MB - PDF) View document
Study results
Study results

GS-FR-292-4043-csr-final-abstract_f-redact

English (904.52 KB - PDF) View document
Study report
Other information